Litigation Details for Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2021)

Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2021)

Docket		Date Filed	2021-10-29
Court	District Court, D. Delaware	Date Terminated	2023-11-13
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,993,941; 11,026,931; 11,026,939; 11,040,029
Link to Docket	External link to docket

Details for Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-10-29				External link to document

Neurocrine Biosciences v. Zydus Pharmaceuticals Patent Litigation: Case No. 1:21-cv-01553

Last updated: August 31, 2026

Neurocrine Biosciences sued Zydus Pharmaceuticals in the U.S. District Court for the District of Delaware after Zydus filed an abbreviated new drug application seeking approval for a generic version of Ingrezza, whose active ingredient is valbenazine. The case concerned Orange Book-listed patents covering valbenazine products and methods of treating tardive dyskinesia.

The litigation was resolved through a settlement and dismissal rather than a reported trial judgment. The agreement limited near-term generic launch risk for Neurocrine while preserving a later market-entry pathway for Zydus. The case is strategically important because Ingrezza is Neurocrine's principal commercial product and generated more than $1 billion in annual net sales during the relevant period.

What was Neurocrine Biosciences v. Zydus Pharmaceuticals about?

The dispute involved Zydus's ANDA for generic valbenazine capsules. Neurocrine alleged that Zydus's ANDA product would infringe patents listed for Ingrezza in the FDA's Orange Book.

Item	Information
Court	U.S. District Court for the District of Delaware
Case number	1:21-cv-01553
Plaintiff	Neurocrine Biosciences, Inc.
Defendant	Zydus Pharmaceuticals (USA) Inc.
Product	Ingrezza, valbenazine capsules
Regulatory pathway	ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act
Dispute type	Hatch-Waxman patent infringement litigation
Filing period	2021
Outcome	Settlement and dismissal
Product indication	Tardive dyskinesia and chorea associated with Huntington's disease
FDA product sponsor	Neurocrine Biosciences

Neurocrine filed the action after receiving Zydus's Paragraph IV certification. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. Filing the lawsuit within the statutory period triggered a 30-month stay of FDA approval, subject to statutory exceptions and court developments. [1][2]

Which patents did Neurocrine assert against Zydus?

The litigation involved patents associated with Ingrezza's valbenazine product and approved therapeutic uses. Public case and FDA records identify the dispute as part of Neurocrine's broader Ingrezza patent enforcement program, which included patents directed to valbenazine formulations, compositions, and treatment methods.

The principal patent numbers associated with the litigation and Ingrezza's Orange Book estate include the following:

Patent	General subject matter	Role in Ingrezza estate
U.S. Patent No. 10,583,138	Valbenazine-related pharmaceutical use or product claims	Listed Ingrezza patent asserted in generic litigation
U.S. Patent No. 10,716,793	Valbenazine treatment or composition claims	Listed Ingrezza patent asserted in generic litigation
U.S. Patent No. 11,147,878	Later-issued valbenazine protection	Supplemental Orange Book protection
U.S. Patent No. 11,266,639	Later-issued product or use protection	Supplemental Orange Book protection
U.S. Patent No. 11,925,680	Later-issued Ingrezza protection	Extended estate for later regulatory activity

The exact claims at issue depend on Zydus's ANDA certification and the operative complaint. Hatch-Waxman complaints generally identify the relevant patent claims and allege that the proposed ANDA labeling, dosage form, active ingredient, or manufacturing process would infringe those claims under 35 U.S.C. § 271(e)(2).

The litigation should not be analyzed solely through the expiration date of the earliest valbenazine patent. Later-issued formulation and method-of-use patents can materially affect generic entry even after an earlier compound patent expires.

What was the FDA and Orange Book status of Ingrezza?

Ingrezza received FDA approval in 2017 for tardive dyskinesia. The FDA later expanded the label to include chorea associated with Huntington's disease. Neurocrine markets valbenazine in capsule strengths that include 40 mg, 60 mg, and 80 mg.

The Orange Book identifies patents that the NDA holder represents as covering the approved drug or approved methods of use. An Orange Book listing does not establish validity or infringement. It does, however, create the principal regulatory mechanism for delaying ANDA approval after a Paragraph IV certification.

FDA milestones

Date	Regulatory event
2017	FDA approval of Ingrezza for tardive dyskinesia
2023	FDA approval of an expanded indication for chorea associated with Huntington's disease
2021	Zydus ANDA litigation initiated after Paragraph IV activity
2020s	Neurocrine continued adding or enforcing later-issued patents covering the Ingrezza franchise

The 30-month stay is a regulatory stay on final ANDA approval. It does not automatically prohibit a generic applicant from launching at risk after approval, and it does not prevent the parties from settling before trial.

When does valbenazine lose exclusivity?

Valbenazine does not have one single exclusivity date. Its commercial protection consists of FDA regulatory exclusivity, patents, pediatric extensions if applicable, and settlement-based launch restrictions.

The practical generic-entry date depends on:

1. The expiration of the patents listed in the ANDA litigation.
2. Any patent-term adjustment or extension.
3. The terms of Neurocrine's settlement with Zydus.
4. Whether Zydus's ANDA receives tentative or final approval.
5. Whether later patents are asserted against the same or a modified ANDA.
6. Whether another generic applicant obtains an earlier settlement or court judgment.

The earliest core patent expiration is not necessarily the effective end of Ingrezza exclusivity. Method-of-use and formulation patents can remain commercially relevant after an earlier patent expires, although their ability to block a generic depends on the ANDA label and the specific claims.

What was the outcome of the Neurocrine-Zydus lawsuit?

The case ended without a reported merits decision invalidating or upholding the asserted patents. The parties entered into a settlement, and the action was dismissed from the Delaware docket.

The public resolution indicates that:

• Zydus did not obtain an immediate unrestricted launch through a final trial judgment.
• Neurocrine avoided the risk of an adverse validity, enforceability, or infringement ruling.
• Zydus obtained a contractual route to enter the valbenazine market at a later date or under conditions established by the settlement.
• The agreement likely included a license or authorized-launch mechanism, although detailed commercial terms were not publicly disclosed in the court docket.
• The settlement did not create binding precedent on the validity of the asserted patents.

A dismissal following settlement is materially different from a judgment after claim construction, summary judgment, or trial. It leaves the patents formally untested in that action and preserves their potential value against other ANDA filers, subject to collateral-estoppel and settlement-related issues.

Did Zydus launch a generic version of Ingrezza?

The litigation record does not establish an immediate commercial generic launch by Zydus. Settlement dismissal should not be treated as proof that Zydus had unrestricted FDA approval or an unrestricted right to market valbenazine.

Generic launch can occur through several pathways:

Launch scenario	Effect on Neurocrine
Authorized launch under settlement	Controlled erosion beginning on the agreed launch date
At-risk launch before final patent resolution	High litigation exposure for Zydus and potential damages or injunction risk
Skinny-label launch	May avoid some method-of-use claims but cannot eliminate product or formulation patent risk
Post-expiration launch	Broadest generic substitution potential
Delayed or contingent launch	Preserves Neurocrine revenue while giving Zydus an assured entry pathway

For Ingrezza, a skinny-label strategy would be difficult to evaluate because the product's commercial value is tied to approved movement-disorder indications and dosing regimens. The effectiveness of a label carve-out would depend on the asserted claims and the final ANDA label.

How strong was Neurocrine's patent estate?

Neurocrine's estate was commercially meaningful but had mixed legal characteristics.

Strengths

• Multiple Orange Book-listed patents created several litigation positions.
• The estate included later-issued patents, reducing reliance on one early patent.
• Valbenazine has specialized pharmacology and dosage requirements, which may support formulation and treatment-method claims.
• The principal product had substantial sales, increasing the economic value of maintaining exclusivity.
• Settlements can delay generic erosion without requiring the patent holder to expose claim validity to a final judgment.

Weaknesses

• Method-of-use patents are vulnerable to label-carve-out strategies.
• Generic applicants can challenge claim scope, written description, enablement, obviousness, and infringement.
• Later-issued patents may face prior-art challenges or prosecution-history limitations.
• The commercial scope of a settlement may be narrower than the full scope of the patent estate.
• A court dismissal does not confirm that the patents would survive a validity challenge.

The litigation outcome therefore supports a conclusion of commercial effectiveness, not a definitive conclusion of patent validity.

What generic entry risks exist for Ingrezza?

The principal risk is a staged erosion of valbenazine revenue rather than an immediate total loss of exclusivity.

Near-term risk

The Zydus settlement reduced the probability of an immediate unrestricted launch. Neurocrine retained time to expand the Ingrezza franchise, defend later patents, and establish additional indications or formulations.

Medium-term risk

A settlement-authorized launch by Zydus can establish price pressure before all Orange Book patents expire. The magnitude depends on whether Zydus receives first-to-file benefits, whether other ANDA applicants enter, and whether pharmacy substitution applies.

Long-term risk

Multiple generic manufacturers could enter after the relevant patent barriers lapse. Valbenazine's capsule product is more exposed to conventional generic competition than a complex biologic or device-based delivery system. The product's manufacturing process may create technical barriers, but it is not expected to provide the same durable protection as a biologic manufacturing platform.

Which companies challenged Ingrezza patents?

Neurocrine faced a broader generic challenge environment involving multiple ANDA applicants, including major generic manufacturers and specialty pharmaceutical companies. The Zydus action was one component of the wider Ingrezza patent program.

The competitive risk should be assessed applicant by applicant because:

• Each ANDA may contain different Paragraph IV certifications.
• Applicants may challenge different patents.
• Settlement dates may differ.
• One applicant may receive an authorized launch earlier than another.
• A court ruling in one case may affect, but does not automatically resolve, another case.

The Zydus dismissal did not eliminate challenges by other ANDA filers or prevent Neurocrine from asserting later-issued patents.

How did the litigation affect Neurocrine's revenue exposure?

Ingrezza was Neurocrine's primary revenue driver during the litigation period. Neurocrine reported Ingrezza net product sales of approximately $1.4 billion in 2023, making generic-entry timing a material valuation issue. [3]

A delayed Zydus launch protected the highest-value period of the product's lifecycle. The economic effect of a later authorized generic depends on:

• The number of entrants at launch.
• The launch date relative to patent expiry.
• Wholesale acquisition price discounts.
• Pharmacy benefit manager contracting.
• Generic substitution rules.
• Whether Zydus sells under its own label or as an authorized generic.
• The speed of additional generic approvals.

Even a single generic entrant can reduce net price, but multisource competition usually produces substantially greater erosion.

What litigation and licensing issues remain after dismissal?

The settlement resolved the specific case, not every possible dispute concerning valbenazine.

Potential continuing issues include:

• Enforcement of the settlement's launch provisions.
• Compliance with any license restrictions.
• Later litigation involving newly issued patents.
• Separate lawsuits against other ANDA applicants.
• Disputes involving an amended ANDA or new dosage strength.
• Patent challenges to expanded indications.
• Antitrust or reverse-payment scrutiny, depending on the agreement's structure.

Settlement confidentiality limits public assessment of the precise launch date, royalty terms, license scope, and restrictions on Zydus. The docket's dismissal should therefore be read as a procedural conclusion of the action, not as a public disclosure of the agreement's full economics.

How does this case compare with biosimilar litigation?

This was a small-molecule Hatch-Waxman case, not a biologic biosimilar dispute.

Issue	Neurocrine v. Zydus	Biosimilar litigation
Product	Small-molecule valbenazine	Biologic reference product
FDA pathway	ANDA	351(k) biosimilar application
Principal statute	Hatch-Waxman	Biologics Price Competition and Innovation Act
Patent process	Paragraph IV certification and 30-month stay	Patent dance and related BPCIA procedures
Substitution	Generally governed by generic substitution rules	Depends on interchangeability designation and state law
Manufacturing risk	Chemical synthesis and dosage-form controls	Cell-line, process, and analytical comparability barriers

Biosimilar risk is not a direct issue in this case because valbenazine is a chemically synthesized active pharmaceutical ingredient.

Key Takeaways

• Case No. 1:21-cv-01553 was a Hatch-Waxman action over generic valbenazine capsules.
• Neurocrine alleged infringement of Orange Book-listed Ingrezza patents after Zydus's Paragraph IV activity.
• The case ended through settlement and dismissal, without a reported trial judgment on patent validity or infringement.
• The settlement reduced immediate generic-entry risk but did not eliminate long-term erosion.
• Later-issued formulation and method-of-use patents remain relevant to the broader Ingrezza patent estate.
• Ingrezza's high revenue concentration made generic launch timing a significant commercial issue.
• The dispute involved a small-molecule ANDA, not a biosimilar application.
• Public docket materials do not establish unrestricted immediate Zydus commercialization.

FAQs About Neurocrine Biosciences v. Zydus

What drug was at issue in the Zydus lawsuit?

The product was Ingrezza, whose active ingredient is valbenazine. Ingrezza is approved for tardive dyskinesia and chorea associated with Huntington's disease.

Did Zydus win the Ingrezza patent case?

No merits victory was reported. The action was resolved through settlement and dismissal, leaving no public judgment that the asserted patents were invalid or not infringed.

Can Zydus sell generic valbenazine after the settlement?

Only according to the settlement's terms and the status of Zydus's FDA approval. A dismissal alone does not establish an unrestricted right to market generic valbenazine.

Are Ingrezza patents listed in the Orange Book?

Yes. FDA records identify multiple patents associated with Ingrezza, including patents covering valbenazine-related products, formulations, and methods of use.

Is Neurocrine exposed to biosimilar competition for Ingrezza?

No. Ingrezza is a small-molecule drug regulated through the ANDA pathway. Its principal competitive threat is generic valbenazine, not a biosimilar.

References

1. U.S. District Court for the District of Delaware. (2021-2024). Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:21-cv-01553. PACER/CourtListener docket records.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. Neurocrine Biosciences, Inc. (2024). 2023 annual report on Form 10-K. U.S. Securities and Exchange Commission.

4. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 10,583,138; 10,716,793; 11,147,878; 11,266,639; and 11,925,680. USPTO.

5. U.S. Food and Drug Administration. (2017-2023). Ingrezza prescribing information and approval history. FDA.